Sharon Cload

SHARON CLOAD is VP of discovery biotherapeutics at Bristol Myers Squibb (BMS). In this role, her team works in partnership with the Immunology, Cardiovascular, and Fibrosis (ICF) and Mechanisms of Cancer Resistance (MoCR) Thematic Research Centers. In 2008, Cload joined Adnexus, a BMS R&D company, to lead the evolution of their core biologics discovery platforms. She was part of the team that launched BMS’ site in Kendall Square in 2018 and looks forward to the opening of the new larger research center at Cambridge Crossing in 2023. She has enjoyed being part of the vibrant Cambridge life sciences ecosystem in both biotech and pharma settings throughout her career. Prior to BMS, she led discovery teams at Archemix Corp. and Scriptgen Pharmaceuticals. She is a member of the MassBio board of directors, and she is passionate about cultivating relationships within the entrepreneurial community to enable science that will benefit patients. @bmsnews